Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rEV131 for Ocular Inflammation After Cataract Surgery
NCT00353964Phase 2Unknown
- Sponsor
- Nanoco
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rEV131 in ocular inflammation (5 arms), sponsored by Nanoco. Primary endpoint: Ocular Inflammation at Day 14. Status: unknown.
02
Drugs
rEV131
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on NCT00353964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00353964.